Valuation: Alkermes plc

Market Cap 8.11B 6.95B 6.5B 5.95B 11.16B 776B 11.31B 76.78B 29.94B 390B 30.44B 29.78B 1,289B P/E 2026 *
-94.7x
P/E 2027 * 66.5x
Enterprise Value 8.85B 7.58B 7.09B 6.49B 12.19B 847B 12.35B 83.82B 32.69B 425B 33.24B 32.51B 1,407B EV / Sales 2026 *
4.85x
EV / Sales 2027 * 4.51x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.65%
1 week-1.49%
Current month-1.35%
1 month-8.55%
3 months+30.80%
6 months+51.46%
Current year+72.73%
1 week 47.33
Extreme 47.33
51.29
1 month 47.33
Extreme 47.33
53.88
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
17/8/26 Sell

Executive/Senior Manager

-7,576 0.0045%
5/8/26 Free

Chief Executive Officer

217,534 0.1297%
3/8/26 Sell

Compliance Officer

-2,034 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%-1.49%+66.31%+63.06% 8.11B
+1.09%+5.26%+4.44%+26.03% 51.61B
-1.07%+2.82%+474.18%+601.24% 44.89B
+1.47%+9.79%+40.15%+21.21% 42.77B
+1.44%+7.77%+19.27%+90.94% 42.58B
-0.93%-4.33%+17.87%+51.96% 31.82B
+1.32%+7.30%+36.93%+152.36% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+7.12%+35.49% 14.76B
+1.28%+5.41%+91.01%+46.93% 14.09B
Average +0.47%+3.84%+84.14%+121.02% 28.46B
Weighted average by Cap. +0.49%+4.54%+101.47%+145.94%

Financials

2026 *2027 *
Net sales 1.82B 1.56B 1.46B 1.34B 2.51B 175B 2.55B 17.28B 6.74B 87.71B 6.85B 6.7B 290B 1.94B 1.67B 1.56B 1.43B 2.68B 186B 2.71B 18.42B 7.18B 93.48B 7.3B 7.14B 309B
Net income -89.92M -77.02M -72.07M -65.97M -124M -8.6B -125M -851M -332M -4.32B -338M -330M -14.3B 120M 103M 96.41M 88.25M 166M 11.51B 168M 1.14B 444M 5.78B 452M 442M 19.12B
Net Debt 744M 637M 596M 546M 1.02B 71.18B 1.04B 7.04B 2.75B 35.76B 2.79B 2.73B 118B 670M 574M 537M 492M 922M 64.1B 935M 6.34B 2.47B 32.2B 2.52B 2.46B 107B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
21/08/26 USD 48.33 +0.65% 939,635
20/08/26 USD 48.02 -4.30% 1,635,207
19/08/26 USD 50.18 +1.41% 1,544,219
18/08/26 USD 49.48 -0.74% 970,918
17/08/26 USD 49.85 +1.61% 764,040
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
48.33USD
Average target price
56.00USD
Spread / Average Target
+15.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock